Get the Daily Brief
Latest Biotech News
FDA clears Jascayd for IPF — first new oral option in years
Boehringer Ingelheim won FDA approval for Jascayd (nerandomilast), a preferential PDE4B inhibitor, marking the first U.S. approval for idiopathic pulmonary fibrosis (IPF) in over a decade....
AstraZeneca inks up to $555M deal with Algen for AI‑driven discovery
AstraZeneca agreed a multi‑year collaboration valued at up to $555 million with Algen Biotechnologies to use Algen’s AlgenBrain platform — a CRISPR‑AI functional genomics system — to identify...
Big rounds fuel late‑stage pushes: Expedition $165M, Arthrosi $153M
Two large financings highlight renewed private capital activity: Expedition Therapeutics closed a $165 million Series A to advance EXPD‑101, a DPP1 inhibitor for COPD, while Arthrosi Therapeutics...
Novo buys Akero for $4.7B – FGF21 play in MASH
Novo Nordisk agreed to acquire Akero Therapeutics in a deal valuing the company at roughly $4.7 billion upfront to secure efruxifermin, an FGF21‑mimetic in late‑stage development for metabolic...
FDA clears Jascayd — first new IPF pill in years
The U.S. Food and Drug Administration approved Jascayd (nerandomilast), an oral preferential PDE4B inhibitor developed by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF). The approval...
Tempus wins $60.5M ARPA‑H contract: precision cancer testing
Tempus AI was awarded a $60.5 million five‑year contract by ARPA‑H to provide testing and contract research organization services for the ADAPT precision cancer therapy program. Under the...
Intellia updates in vivo programs — HAE lead shows durable kallikrein cut
Intellia provided a clinical update at ESGCT reporting durable pharmacodynamic activity from its in vivo LNP gene‑editing programs. The company highlighted NTLA‑2002 (lonvo‑z) for hereditary...
Proteins programmed with Boolean logic: autonomous targeting advances
Researchers at the University of Washington described a new class of engineered proteins that perform Boolean logic gating—AND, OR and YES—to control drug localization and release in response to...
‘Super‑adjuvant’ nanoparticle vaccine prevents tumors in mice — multi‑cancer proof
University of Massachusetts Amherst researchers reported a nanoparticle vaccine that combines cancer‑specific antigens with a multi‑pathway 'super' adjuvant to prevent tumor formation and...
Chiesi inks up‑to‑$2.1B Arbor pact to advance PH1 gene editing
Chiesi Group signed an exclusive collaboration and license agreement with Arbor Biotechnologies to develop and potentially commercialize Arbor’s lipid‑nanoparticle delivered gene‑editing candidate...
Pan‑disease blood proteome atlas: 59 diseases profiled in Science
An international consortium led by researchers at KTH/SciLifeLab published a comprehensive pan‑disease blood proteome atlas in Science, profiling proteins across more than 8,200 people spanning 59...
Serial biopsies expose hidden glioblastoma therapy effects – MRI misses signals
Multi‑institutional teams reported that longitudinal tumor biopsies in recurrent glioblastoma provide pharmacodynamic and immune‑response signals not captured by routine MRI. A Mass General...
FDA adds DPYD boxed warning to Xeloda label — germline testing advised
The FDA updated Genentech’s Xeloda (capecitabine) label to include explicit language recommending testing for DPYD variants before initiating therapy, and added a boxed warning noting that...
Novo Nordisk Buys Akero for $4.7 Billion – MASH Play
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash, adding the late‑stage FGF21 analogue efruxifermin to its metabolic disease portfolio. Novo expects efruxifermin—in Phase...
Global Proteome Atlas... 9K Samples Reveal Disease Signatures
Researchers led by KTH/SciLifeLab published a large-scale proteomic dataset profiling 9,027 blood samples across more than 59 diseases using Olink’s Explore platforms. The cohort combined...
FDA Clears Boehringer’s Jascayd: First New IPF Drug in a Decade
The FDA approved Jascayd (nerandomilast), a preferential PDE4B inhibitor from Boehringer Ingelheim, for idiopathic pulmonary fibrosis (IPF), marking the first new therapy for the indication in...
Sanofi’s AlphaMedix Hits Phase 2 Goals – Targeted Alpha Shows Promise
Sanofi reported that AlphaMedix, a targeted alpha‑emitting radioligand developed with Orano Med, met primary endpoints in a Phase 2 trial for gastroenteropancreatic neuroendocrine tumors...
Tempus Wins $60.5M ARPA‑H Contract: AI Tools for Precision Cancer
Tempus was awarded a $60.5 million, five‑year contract from ARPA‑H to provide testing and contract research services for the ADAPT precision cancer therapy program. Under the award, Tempus will...
Mammoth Plans First Trial of Gene Editing to Permanently Lower Triglycerides
Mammoth Biosciences disclosed preclinical monkey data and plans for a first‑in‑human study of an in vivo gene editing candidate designed to durably lower triglycerides. The program uses Mammoth’s...
Intellia Clinical Update: In Vivo Editing Programs Advance
Intellia Therapeutics delivered a clinical update at ESGCT highlighting progress across its in vivo LNP‑based gene‑editing programs. The company reported multi‑year durability signals in depooled...